Ventilator-associated Pneumonia Clinical Trial
Official title:
Study on Dynamic Environmental Exposome of ICU and the Establishment of Microbial Transmission Model Between Environment and Host
HAI (Hospital-acquired infection) is very common in ICUļ¼and lack of understanding of environmental exposure omics and environment-host microbial interactions restricts the prevention and control of HAI. In this project, the investigators try to analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the ICU environment through metagenome.
This observational study aims to analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the ICU environment. The investigators will conduct weekly air microbiome sampling and microbiome sampling at 5 high-frequency contact points in different types of ICU units in three hospitals for one consecutive year, and collect dynamic pharyngeal swabs from ICU ward health care workers and dynamic clinical specimens (endotracheal aspiration, and bronchoalveolar lavage fluid) from patients with ventilator-associated pneumonia in ICU ward. With DNA high-throughput sequencing technology, the investigators will analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the ICU environment, and provide support for HAI prevention. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01406951 -
Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients
|
N/A | |
Completed |
NCT00893763 -
Strategies To Prevent Pneumonia 2 (SToPP2)
|
Phase 2 | |
Recruiting |
NCT03581370 -
Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia
|
Phase 3 | |
Completed |
NCT02070757 -
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
|
Phase 3 | |
Completed |
NCT03348579 -
Hospital-acquired Pneumonia in Intensive Care Unit
|
||
Completed |
NCT04242706 -
VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs
|
Phase 4 | |
Recruiting |
NCT05589727 -
Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
|
||
Not yet recruiting |
NCT06168734 -
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
|
Phase 3 | |
Completed |
NCT02515448 -
A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia
|
Phase 1 | |
Completed |
NCT01972425 -
Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship
|
N/A | |
Completed |
NCT02838160 -
Effectiveness of Different Educational Strategies on the KAP, Psychological and Clinical Outcomes
|
N/A | |
Completed |
NCT01467648 -
The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
|
Phase 4 | |
Completed |
NCT00364299 -
Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure
|
N/A | |
Not yet recruiting |
NCT03018431 -
CT Scan and Lung Ultrasonography to Improve Diagnostic of Ventilation Acquired Pneumonia in ICU
|
N/A | |
Completed |
NCT02515617 -
Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)
|
N/A | |
Completed |
NCT02585180 -
Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia
|
N/A | |
Completed |
NCT02583308 -
Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation
|
N/A | |
Recruiting |
NCT01546974 -
Ventilator-associated Pneumonia (VAP) and Humidification System
|
Phase 4 | |
Completed |
NCT02060045 -
Prevention Ventilator Associated Pneumonia
|
N/A | |
Terminated |
NCT00543608 -
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
|
Phase 2 |